Gain Therapeutics, Inc. (GANX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.18

From 52W high−73.44%

Volume228073.00

Market cap$48.44M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.18

From 52W high

−73.44%

Volume

228073.00

Market cap

$48.44M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.9x

P/E (TTM)

—

RSI (14)

32.3

MomentumView details →

1D Return

−3.48%

YTD Return

−63.66%

SummaryUpdated Jun 1, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) is a clinical-stage biotechnology company founded in 2017 and headquartered in Bethesda, Maryland. The company went public in March 2021 and focuses on developing novel therapies for rare genetic diseases and neurological disorders caused by protein misfolding. Gain Therapeutics utilizes its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to discover and develop small molecule treatments that can restore proper protein function in patients with devastating genetic conditions.

Ask drillr about Gain Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

4.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−178.06%

ROA (TTM)

−130.37%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+24.24%

FCF YoY

−2.71%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+31.46%

EBITDA YoY

−7.63%

MomentumView details →

1D Return

−3.48%

YTD Return

−63.66%

1Y Return

−36.41%

RSI (14)

32.3

vs 50D SMA

−25.61%

vs 200D SMA

−36.71%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

4.36x

Quick Ratio

4.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

20.29%

Beats (12Q)

5/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

10.43%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−20.11M

Op. CF (TTM)

−18.95M

Next earningsNov 11, 2026 →

Latest newsMore news →

Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, with an annual base salary of $275,000 and a target bonus of 35% of base salary.7d ago

Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing stable MDS-UPDRS motor scores and no disease progression in 12 evaluable participants who completed 12 months of daily oral administration by August 31, 2026.34d ago

Similar companies

Mereo BioPharma Group plcMREO Kalaris Therapeutics IncKLRS Connect Biopharma Holdings LimitedCNTB Caribou Biosciences, Inc.CRBU Genenta Science S.p.A.GNTA GridAI Technologies Corp.GRDX Find similar companies →

Latest newsMore news →

Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, with an annual base salary of $275,000 and a target bonus of 35% of base salary.7d ago Gain Therapeutics presented positive Phase 1b open-label extension data for rexaceract, showing stable MDS-UPDRS motor scores and no disease progression in 12 evaluable participants who completed 12 months of daily oral administration by August 31, 2026.34d ago